— Know what they know.
Not Investment Advice

KLRA NASDAQ

Kailera Therapeutics, Inc.
1W: -12.0% 1M: -20.3% YTD: -24.5%
$19.62
+0.07 (+0.36%)
Pre-Market: $20.43 (+0.81, +4.13%)
Weekly Expected Move ±10.2%
$17 $19 $21 $23 $25
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 34 · $2.5B mcap · 89M float · 1.28% daily turnover · Short 64% of daily vol
Smart Money Score
Moderate 50
Insider+$326.8M
Congress
ETF Holdings
Key Statistics
Market Cap$2.5B
52W Range19.01-28.23
Volume345,142
Avg Volume1,145,204
Beta0.00
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEORonald C. Renaud Jr.
Employees145
SectorHealthcare
IndustryBiotechnology
IPO Date2026-04-17
180 Third Avenue, 4th Floor
Waltham, MA 02451
US
(781) 317-0290
About Kailera Therapeutics, Inc.

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.

Recent Insider Trades

NameTypeSharesPriceDate
RTW INVESTMENTS, LP P-Purchase 500,000 $16.00 2026-04-20
RTW INVESTMENTS, LP C-Conversion 10,276,820 2026-04-20
RTW INVESTMENTS, LP C-Conversion 8,250,000 2026-04-20
RTW INVESTMENTS, LP C-Conversion 2,026,820 2026-04-20
Jiangsu Hengrui Phar C-Conversion 9,477,719 2026-04-20

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms